---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000013"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:42:12.119768+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M

## Summary
- FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).
- Q4 GAAP net income $2.7M ($0.03/share) vs net loss $60.3M in Q4 2024; non-GAAP net income $33.3M.
- PDUFA target for FILSPARI in FSGS is April 13, 2026; commercial launch preparations ongoing.
- Cash & securities $322.8M at Dec 31, 2025; expects $25M milestone from Mirum in H1 2026.
- Phase 3 HARMONY study of pegtibatinase in HCU resumed enrollment; primary endpoint tHcy change.

## SEC filing metadata
- accession: 0001438533-26-000013
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/0001438533-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/tvtx-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000013
- JSON: https://secwatch.observer/filing/0001438533-26-000013.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.